Estrogen hormones are implicated in a majority of breast cancers and estrogen receptor alpha (ER), the main nuclear factor mediating estrogen signaling, orchestrates a complex molecular circuitry that is not yet fully elucidated. Here, we investigated genome-wide DNA methylation, histone acetylation and transcription after estradiol (E2) deprivation and re-stimulation to better characterize the ability of ER to coordinate gene regulation. We found that E2 deprivation mostly resulted in DNA hypermethylation and histone deacetylation in enhancers. Transcriptome analysis revealed that E2 deprivation leads to a global down-regulation in gene expression, and more specifically of TET2 demethylase that may be involved in the DNA hypermethylation f...
Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes ...
Breast cancer is the most common cancer among women and two thirds of all breast cancers are classif...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
Estrogen hormones are implicated in a majority of breast cancers and estrogen receptor alpha (ER), t...
Previous epidemiological and experimental studies have strongly implicated estrogens in breast cance...
Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient receives endocrin...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
BACKGROUND: Estrogens regulate diverse physiological processes in various tissues through genomic an...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
Up to 40% of patients with oestrogen receptor-positive (ER+) breast cancer develop resistance to end...
The human genome is organised into a DNA-protein complex called chromatin, of which the main repeati...
Background: In human Estrogen Receptor alpha (ER alpha)-positive breast cancers, 59 end dense methyl...
Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer,...
Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes ...
Breast cancer is the most common cancer among women and two thirds of all breast cancers are classif...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
Estrogen hormones are implicated in a majority of breast cancers and estrogen receptor alpha (ER), t...
Previous epidemiological and experimental studies have strongly implicated estrogens in breast cance...
Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient receives endocrin...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechani...
BACKGROUND: Estrogens regulate diverse physiological processes in various tissues through genomic an...
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, ...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...
Up to 40% of patients with oestrogen receptor-positive (ER+) breast cancer develop resistance to end...
The human genome is organised into a DNA-protein complex called chromatin, of which the main repeati...
Background: In human Estrogen Receptor alpha (ER alpha)-positive breast cancers, 59 end dense methyl...
Endocrine therapy has successfully been used to treat estrogen receptor (ER)-positive breast cancer,...
Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes ...
Breast cancer is the most common cancer among women and two thirds of all breast cancers are classif...
The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several targeted ther...